| Document |
Document Title |
|
WO/2023/143236A1 |
Disclosed are a 2H-indazole-7-formamide compound, a preparation method, a pharmaceutical composition, and an application. The structure of the compound is represented by formula (I), and comprises an isomer or pharmaceutically acceptable...
|
|
WO/2023/143494A1 |
The present invention relates to a bifunctional PROTAC compound having a structure as represented by formula (I) or formula (IV), CLM-L-PTM (I), or ULM-L-PTM (IV) or a pharmaceutically acceptable salt thereof, and a preparation method th...
|
|
WO/2023/143576A1 |
Disclosed are a crystalline form or an amorphous form of a macrocyclic compound or a salt or solvate thereof, as well as a preparation method therefor and an application thereof. The structure of the macrocyclic compound is represented b...
|
|
WO/2023/143491A1 |
The present invention relates to a synthesis method for a 7,8-dihydro-2H-cyclopenta[4,5]pyrrolo[1,2-a]pyrazine-1(6H)-o
ne compound and an analog thereof. The method has simple steps and simple and safe operations in a reaction process an...
|
|
WO/2023/144793A1 |
The present invention relates to compounds of formula (I), that possess DNA polymerase theta (POLQ) enzyme inhibitory activity, methods for their preparation, pharmaceutical compositions containing them, and their use in the treatment or...
|
|
WO/2023/143389A1 |
The present disclosure relates to a fused heterocyclic compound, a preparation method therefor, and a medical application thereof. Specifically, the present disclosure relates to a fused heterocyclic compound represented by general formu...
|
|
WO/2023/143546A1 |
The present invention provides compounds having a structure of formula I and excellent Wnt pathway inhibitory activity, or pharmaceutically acceptable salts, isotope derivatives, and stereoisomers thereof. The present invention also prov...
|
|
WO/2023/144559A1 |
The present invention relates to compounds of formula I shown below: wherein R1, R4, R5 and R6 are each as defined in the application. The present invention also relates to processes for the preparation of these compounds, to pharmaceuti...
|
|
WO/2023/143424A1 |
The present invention relates to a compound as represented by general formula (I) or a stereoisomer, a tautomer, a deuterated substance, a solvate, a prodrug, a metabolite, a pharmaceutically acceptable salt, or an eutectic thereof, an i...
|
|
WO/2023/142641A1 |
Provided are a compound of formula I, a stereoisomer or a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising the compound, a preparation method for the compound and a use thereof in preparation of drugs for...
|
|
WO/2023/144160A1 |
The invention provides new heterocyclic compounds having the general formula (I) wherein A and R1 to R4 are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the comp...
|
|
WO/2023/143630A1 |
The present invention relates to the technical field of pharmacy, and in particular to a preparation method for a nucleoside analogue VV116 (a compound of formula (I)). The preparation method provided in the present invention specificall...
|
|
WO/2023/147015A1 |
The invention relates to a compound represented by formula (I) or a pharmaceutically acceptable salt thereof, and associated methods of treating cancer.
|
|
WO/2023/141852A1 |
Disclosed are compounds represented by formula 1a or formula 1b, and respective optical isomers, prodrugs, or pharmaceutically acceptable salts, and pharmaceutical compositions thereof, and the use thereof in the preparation of CDK2 inhi...
|
|
WO/2023/147603A2 |
Disclosed herein are acid addition salt and salt crystals of (6aR, 9aS)-5,6a,7,8,9,9a-hexahydro-5-methyl-3-(phenylamino)-2-((4(
6-fluoropyridin-2-yl)phenyl)methyl)-cyclopent[4,5]imidazo[1,
2-a]pyrazolo[4,3-e]pyrimidin-4(2H)-one, composit...
|
|
WO/2023/147468A1 |
The present disclosure relates to compounds that act as inhibitors of NLRP3 inflammasomes; pharmaceutical compositions comprising the compounds; and methods of treating disorders associated with inflammation and inflammaging, including h...
|
|
WO/2023/147418A1 |
Provided herein is a compound of Formula (I) or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or deuterated analog thereof, a pharmaceutical composition comprising a compound of the present invention, togeth...
|
|
WO/2023/147311A1 |
The present disclosure provides a substituted pyrazolopyrimidine, 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-
4-(trifluoromethyl)-1 H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine, or a salt, solvate, hydrate, or co...
|
|
WO/2023/144761A1 |
The present invention relates to an industrially feasible and economically viable process for preparation of Anagrelide Hydrochloride Monohydrate of formula (1a).
|
|
WO/2023/147531A1 |
Disclosed are compounds of Formula (I) pharmaceutically acceptable salts thereof are defined herein, and pharmaceutical compositions thereof and combinations thereof, and methods of using the same as inhibitors of protein tyrosine phosph...
|
|
WO/2023/142985A1 |
The present invention belongs to the technical field of drug synthesis. Disclosed is a preparation method for a TGF-β-inhibiting anti-tumor drug. Compared with preparation methods in the existing technology, the number of reaction steps...
|
|
WO/2023/137634A1 |
Provided in the present invention are a tricyclic compound as shown in the following formula I, the preparation therefor, a pharmaceutical composition and the use. The compound provided by the present invention can be used as an inhibito...
|
|
WO/2023/140173A1 |
Provided is a material for photoelectric conversion elements for imaging which renders increases in sensitivity and resolution possible. The material for photoelectric conversion elements for imaging comprises a thiophene derivative repr...
|
|
WO/2023/139125A1 |
The presented invention relates to a process for preparation of Copanlisib, compound of formula (1), or a salt or a solvate thereof comprising:.
|
|
WO/2023/138583A1 |
Provided in the present invention are a heterocyclic compound, a pharmaceutical composition and the use thereof. Specifically disclosed are a heterocyclic compound as represented by formula (I-0), a pharmaceutically acceptable salt or st...
|
|
WO/2023/141522A2 |
Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein)...
|
|
WO/2023/140706A1 |
The invention relates to a light-emitting organic molecule, in particular for the application in optoelectronic devices. According to the invention, the organic molecule has - a first chemical moiety comprising of a structure of formula ...
|
|
WO/2023/139085A1 |
The invention relates to a compound of formula (I) wherein A1, A2, A3, R1, R2, R2', R3, R4 and R5 are as defined in the description and in the claims. The compound of formula (I) can be used as a medicament.
|
|
WO/2023/139084A1 |
The invention relates to a compound of formula (I) wherein A1, R1, R2, R3, R4 and R5 are as defined in the description and in the claims. The compound of formula (I) can be used as a medicament.
|
|
WO/2023/137885A1 |
Disclosed in the present invention are a compound having pyridoimidazole as the parent nucleus, and a preparation method for and a use of the compound. The compound having pyridoimidazole as the parent nucleus provided by the present inv...
|
|
WO/2023/138681A1 |
The present invention relates to an acidic salt or a crystal form of a nitrogen-containing fused ring derivative inhibitor, and a preparation method therefor and the use thereof. The salt or crystal form of the inhibitor of the present i...
|
|
WO/2023/141300A1 |
The present disclosure provides compounds and pharmaceutically acceptable salts thereof, and methods of using the same. The compounds and methods have a range of utilities as therapeutics, diagnostics, and research tools. In particular, ...
|
|
WO/2023/139276A1 |
The present invention relates to a process for preparing crystalline sitagliptin hydrochloride monohydrate, compound of formula (IV) from compound of formula (II), Boc sitagliptin, without the need of isolating sitagliptin free base.
|
|
WO/2023/138343A1 |
The present invention relates to a new type pyrazolopyrimidine compound, a composition thereof, a preparation method therefor and the use thereof as an anti-cancer drug having anti-tumor activity. The new type pyrazolopyrimidine compound...
|
|
WO/2023/139241A1 |
The present invention concerns inhibitors of ubiquitin specific protease 7 (USP7), and methods of use thereof. Specifically, the invention provides compounds according to formula (I), including stereoisomers, pharmaceutically acceptable ...
|
|
WO/2023/138662A1 |
Disclosed are a series of benzopyrimidine compounds and a use thereof, and specifically disclosed are compounds represented by formula (II) and pharmaceutically acceptable salts thereof.
|
|
WO/2023/139199A1 |
Compounds of Formula (I) or a pharmaceutically acceptable salt thereof are PROTAC compounds useful in the treatment of prostate cancer.
|
|
WO/2023/139479A1 |
The present invention is directed to compound of formula (I) or a pharmaceutically acceptable salt or a stereoisomer or a tautomer thereof that is useful as MALT-1 inhibitors for the treatment of a disease or disorder dependent on MALT-1...
|
|
WO/2023/141511A1 |
5,6,7,8-Tetrahydro-1,6-naphthyridines substituted in the 6-position with pyrimido[1,2-b]pyridazin-4-one are positive allosteric modulators of the muscarinic acetylcholine receptor M4 (mAChR M4) and may have use in treating neurological a...
|
|
WO/2023/138433A2 |
Disclosed are an amide compound having RIPK1 inhibitory activity, a preparation method therefor, and the use thereof. The structure of the amide compound is shown in general formula I, and the definitions of substituents are as described...
|
|
WO/2023/138524A1 |
Disclosed are a compound having an X-Y-Z structure, and a tautomer, a deuterated compound or a pharmaceutical salt thereof. X is a KRAS protein binding ligand compound, Z is an E3 ligase binding ligand compound, and Y is a linking chain ...
|
|
WO/2023/138362A1 |
The present invention relates to a compound of formula (I), or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, and a use thereof in the preparation of a drug for treating diseases related to WEE1 activity.
|
|
WO/2023/139536A1 |
The present invention provides compounds of formula (I) as poly(ADP-ribose) polymerase 7 (PARP7) inhibitors, methods of preparing them, pharmaceutical compositions containing them and their use in methods of treatment, prevention and/or ...
|
|
WO/2023/139164A1 |
The present invention relates to novel compounds of formula (I) These compounds are inhibitors of CDK9 and are useful in the treatment of a variety of diseases including hyperproliferative diseases, virally induced infectious diseases, a...
|
|
WO/2023/135508A1 |
The present invention relates to pyrrolo[1,2-b]-2-pyridazinone compounds of formula (I), or their isotopic forms, stereoisomers, or pharmaceutically acceptable salts thereof as 5-HT4 receptor agonists. The present invention also describe...
|
|
WO/2023/137353A1 |
Described herein are 15-PGDH inhibitors and methods of utilizing 15-PGDH inhibitors in the treatment of diseases, disorders or conditions. Also described herein are pharmaceutical compositions containing such compounds.
|
|
WO/2023/135057A1 |
The present invention provides compounds of general formula (I) in which A, B, X, Y, R1, R2 and R3 are as described and defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, phar...
|
|
WO/2023/134647A1 |
Provided are a piperazino ring derivative represented by formula (I), a pharmaceutically acceptable salt thereof, a preparation method therefor, and a pharmaceutical composition containing said compound, as well as the use of the compoun...
|
|
WO/2023/137060A1 |
The present disclosure encompasses solid state forms of Rucaparib Tosylate, and pharmaceutical compositions thereof.
|
|
WO/2023/135425A1 |
The invention relates to a compound of formula I, wherein R1, R2, R3, R4, R5, R6, R7, R8a, R8b, R9, A and L are as defined in the specification, or a pharmaceutically acceptable salt or solvate thereof, said compound is useful in the tre...
|
